Annexon's Q2 Net Loss Widens 66% on Soaring R&D Costs

Ticker: ANNX · Form: 10-Q · Filed: Aug 14, 2025 · CIK: 1528115

Sentiment: bearish

Topics: Biotechnology, Clinical Trials, R&D Spending, Net Loss, Cash Burn, Liquidity Risk, Neuroinflammatory Diseases

Related Tickers: ANNX

TL;DR

**ANNX is burning cash fast on R&D, but if their pipeline hits, it's a moonshot; otherwise, expect more dilution.**

AI Summary

Annexon, Inc. reported a significant increase in net loss for the three and six months ended June 30, 2025, primarily driven by a substantial rise in research and development (R&D) expenses. The net loss for the three months ended June 30, 2025, was $49.156 million, up from $29.610 million in the prior year period, representing a 66% increase. For the six months ended June 30, 2025, the net loss more than doubled to $103.512 million from $54.786 million in the same period of 2024. R&D expenses surged to $44.160 million for the three months ended June 30, 2025, a 76% increase from $25.026 million in 2024, and reached $92.339 million for the six-month period, a 101% increase from $45.989 million. The company's cash and cash equivalents increased to $132.288 million as of June 30, 2025, from $49.498 million at December 31, 2024, while short-term investments decreased from $262.519 million to $94.729 million. Annexon had an accumulated deficit of $814.2 million as of June 30, 2025, and projects existing cash and investments will fund operations for at least twelve months, but future viability depends on additional funding and milestone achievements.

Why It Matters

Annexon's escalating R&D expenses, which more than doubled year-over-year to $92.339 million for the first six months of 2025, signal aggressive investment in its late-stage clinical platform. This could be a make-or-break period for investors, as successful clinical trial outcomes could lead to significant upside, while failures would exacerbate losses. For employees, continued R&D investment suggests job stability and growth opportunities within the company's core mission. Customers, specifically patients with neuroinflammatory diseases, stand to benefit from accelerated drug development, potentially gaining access to novel therapies sooner. In the competitive biopharmaceutical landscape, Annexon's increased spending indicates a strong push to differentiate its pipeline, putting pressure on rivals to innovate or risk falling behind.

Risk Assessment

Risk Level: high — Annexon reported an accumulated deficit of $814.2 million as of June 30, 2025, and a net loss of $103.512 million for the six months ended June 30, 2025. The company explicitly states it expects to incur losses and negative cash flows for at least the next several years and its future viability beyond 12 months is dependent on obtaining additional funding, indicating significant financial uncertainty.

Analyst Insight

Investors should closely monitor Annexon's clinical trial progress and upcoming data readouts, as these will be critical catalysts for future funding and stock performance. Given the high burn rate and reliance on future financing, consider this a speculative investment with substantial risk and potential for dilution.

Financial Highlights

net Income
-$103.512M
eps
-$0.71
cash Position
$132.288M

Key Numbers

Key Players & Entities

FAQ

What were Annexon's key financial results for the quarter ended June 30, 2025?

For the three months ended June 30, 2025, Annexon reported a net loss of $49.156 million, an increase from $29.610 million in the prior year. Research and development expenses were $44.160 million, up from $25.026 million in the same period of 2024.

How did Annexon's research and development expenses change in the first half of 2025?

Annexon's research and development expenses significantly increased, reaching $92.339 million for the six months ended June 30, 2025. This is more than double the $45.989 million reported for the six months ended June 30, 2024.

What is Annexon's current liquidity position and future funding outlook?

As of June 30, 2025, Annexon had cash and cash equivalents of $132.288 million and short-term investments of $94.729 million, totaling $227.0 million. Management projects these funds will cover operating expenses for at least twelve months, but future viability depends on obtaining additional equity or debt financing.

What is Annexon's accumulated deficit as of June 30, 2025?

As of June 30, 2025, Annexon reported an accumulated deficit of $814.2 million. This reflects the company's history of losses since its inception due to extensive research and development activities and clinical trials.

What are the primary risks to Annexon's business operations?

The primary risks include the uncertainty of obtaining additional funding on favorable terms, the ability to enter into collaborative agreements with strategic partners, and the success of its future operations. Failure to secure funding could force delays or elimination of research and development programs.

Has Annexon adopted any new accounting pronouncements recently?

Annexon adopted ASU 2023-07, Segment Reporting: Improvements to Reportable Segment Disclosures, on January 1, 2024, for annual requirements and January 1, 2025, for interim requirements. The adoption did not have a material impact on the consolidated financial statements.

What was the net loss per share for Annexon for the six months ended June 30, 2025?

The net loss per share, basic and diluted, for Annexon was $0.71 for the six months ended June 30, 2025. This compares to a net loss per share of $0.43 for the same period in 2024.

How much cash did Annexon use in operating activities during the first half of 2025?

Annexon used $88.126 million in net cash from operating activities for the six months ended June 30, 2025. This is an increase from $49.976 million used in operating activities during the same period in 2024.

What is Annexon's business focus?

Annexon, Inc. is a biopharmaceutical company focused on advancing a late-stage clinical platform of novel therapies. Their primary goal is to develop treatments for people living with devastating classical complement-mediated neuroinflammatory diseases.

What was the total stockholders' equity for Annexon as of June 30, 2025?

As of June 30, 2025, Annexon's total stockholders' equity was $199.017 million. This represents a decrease from $293.105 million as of December 31, 2024.

Risk Factors

Industry Context

Annexon operates in the highly competitive and innovation-driven biotechnology sector, focusing on developing therapies for autoimmune and neurodegenerative diseases. The industry is characterized by long development cycles, significant R&D investment, and high regulatory hurdles. Companies often rely on external funding rounds and strategic partnerships to advance their pipelines.

Regulatory Implications

As a clinical-stage biopharmaceutical company, Annexon is subject to stringent regulatory oversight from bodies like the FDA. The success of its drug candidates hinges on rigorous clinical trials and adherence to evolving regulatory standards. Any delays or failures in the regulatory approval process pose significant risks to the company's future.

What Investors Should Do

  1. Monitor R&D spend closely: While necessary, the significant increase in R&D expenses is driving losses. Investors should track the progress and milestones achieved with this investment.
  2. Assess future funding needs: Given the high cash burn and 12-month runway, investors should anticipate potential future equity offerings or financing rounds, which could lead to dilution.
  3. Evaluate clinical trial progress: The success of Annexon's pipeline is paramount. Investors should closely follow clinical trial results and regulatory updates for key drug candidates.
  4. Compare cash burn to peers: Benchmark Annexon's operating cash burn against similar-stage biopharmaceutical companies to gauge relative efficiency and financial management.

Glossary

Accumulated Deficit
The cumulative net losses of a company that have not been offset by net income or additional paid-in capital. It represents the total historical losses incurred by the company since its inception. (Annexon's accumulated deficit of $814.2 million as of June 30, 2025, underscores its history of operating losses and its reliance on external funding to sustain operations.)
Net cash used in operating activities
The amount of cash a company has spent on activities directly related to its core business operations over a period. A negative number indicates a cash outflow. (Annexon's significant increase in net cash used in operating activities to $88.126 million for the six months ended June 30, 2025, highlights an accelerating cash burn rate.)
Weighted-average shares outstanding
The average number of a company's outstanding shares over a specific period, used to calculate earnings per share (EPS). It accounts for changes in the number of shares during the period. (The increase in weighted-average shares outstanding suggests potential dilution for existing shareholders, as more shares are now outstanding compared to the prior year period.)
Liquidity Runway
The estimated period of time a company can continue to operate using its current cash and cash equivalents before needing additional financing. (Annexon's management projects a liquidity runway of at least twelve months, but this is contingent on continued operations and future funding.)

Year-Over-Year Comparison

Annexon's latest 10-Q filing reveals a significantly deteriorating financial performance compared to the prior year. Net losses have widened considerably, with the six-month net loss more than doubling to $103.512 million. This is primarily driven by a 101% surge in R&D expenses to $92.339 million. While the cash position has improved to $132.288 million, this is partly due to a reduction in short-term investments, and the company faces increased operating cash burn. New risks related to the high burn rate and dependence on future funding are highlighted.

Filing Stats: 4,385 words · 18 min read · ~15 pages · Grade level 16.6 · Accepted 2025-08-14 16:10:50

Key Financial Figures

Filing Documents

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations 2 Condensed Consolidated Statements of Comprehensive Loss 3 Condensed Consolidated Statements of Stockholders' Equity 4 Condensed Consolidated Statements of Cash Flows 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 27 Item 4.

Controls and Procedures

Controls and Procedures 27

—OTHER INFORMATION

PART II—OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 28 Item 1A.

Risk Factors

Risk Factors 28 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 72 Item 3. Defaults Upon Senior Securities 72 Item 4. Mine Safety Disclosures 72 Item 5. Other Information 72 Item 6. Exhibits 73

SIGNATURES

SIGNATURES 74 In this Quarterly Report on Form 10-Q, "we," "our," "us," "Annexon" and the "Company" refer to Annexon, Inc. and its consolidated subsidiary. Annexon, Annexon, Inc., the Annexon logo and other trade names, trademarks or service marks of Annexon are the property of Annexon, Inc. This report contains references to our trademarks and to trademarks belonging to other entities. Trade names, trademarks and service marks of other companies appearing in this report are the property of their respective holders. We do not intend our use or display of other companies' trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. ANNEXON, INC. Condensed Consolidated Balance Sheets (in thousands) June 30, 2025 December 31, 2024 (Unaudited) Assets Current assets: Cash and cash equivalents $ 132,288 $ 49,498 Short-term investments 94,729 262,519 Prepaid expenses and other current assets 3,603 4,444 Total current assets 230,620 316,461 Restricted cash 1,032 1,032 Property and equipment, net 11,650 12,638 Operating lease right-of-use assets 15,974 16,705 Other non-current assets 5,297 3,235 Total assets $ 264,573 $ 350,071 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 11,515 $ 10,426 Accrued and other current liabilities 26,411 17,568 Operating lease liabilities, current 2,716 2,518 Total current liabilities 40,642 30,512 Operating lease liabilities, non-current 24,914 26,454 Total liabilities 65,556 56,966 Commitments and contingencies (Note 5) Stockholders' equity: Common stock 110 109 Additional paid-in capital 1,013,211 1,003,685 Accumulated other comprehensive (loss) income ( 93 ) 10 Accumulated deficit ( 814,211 ) ( 710,699 ) Total stockholders' equity 199,017 293,105 Total liabilities and stockholders' equity $

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing